Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric aGvHD
No-moat Mesoblast achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of USD 6.7 million, compared with a loss of USD 39 million in the prior corresponding period. Total revenue in the period of USD 14.6 million, compared with about USD 1 million in the PC, comprised royalties on sales of Temcell in Japan of USD 1.9 million and up-front payments of around USD 12.8 million from its patent license agreement with TiGenix. We think this bode...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.